Can Fite Biopharma (CANF) Stock Price, Quote, News & History | Benzinga

Can Fite Biopharma Ltd (CANF) Stock Price, Quote, News & History

CANFAMEX

Trade with Public

Trade with Public

$3.37

0.051.51%

At close: Aug 26, 5:00 PM EST

$3.34

0.020.6%

Pre-Market: 7:55 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Stock Report

Key Statistics

Open

-

Close

$3.37

Volume / Avg.

334.00 / 1.37M

Day Range

- - -

52 Wk Range

2.56 - 1.18K

Market Cap

$7.16M

P/E Ratio

-

Dividend Yield

-

Exchange

AMEX

RSI

50

Short Interest

2.9%

Days to Cover

1.66

Recent Can Fite Biopharma Ltd News

Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients

Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, supporting a Phase 2b chemotherapy trial.

Vandana Singh

Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case

Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic disease opportunity.

Akanksha Bakshi

Nasdaq Surges Over 1%; ISM Services PMI Tops Views

U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd, Latham Group Inc, and Can Fite Biopharma surge.

Avi Kapoor

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite stock jumps after Namodenoson improves survival in pancreatic cancer Phase 2a study with a strong safety profile.

Vandana Singh

Dow Surges 100 Points; Abercrombie & Fitch Shares Fall After Q4 Results

US stocks rise, with Dow up 0.25% and NASDAQ up 0.69%. Consumer discretionary shares increase by 1.1%, while energy stocks dip by 0.6%.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-8.95M

Investing Cash Flow (TTM)

-2.00K

Financing Cash Flow (TTM)

9.64M

Free Cash Flow (TTM)

-8.95M

Capital Expenditure (TTM)

-2.00K

Net Change in Cash (TTM)

693.00K

Analyst Trends and Forecast

2

May

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$1.06M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.61

PB Ratio (TTM)

1.29

Earnings Yield % (TTM)

-318.87%

Earnings Yield % (FWD)

-50.89%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.61

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$5.53M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$3.37

Volume / Avg.

334.00 / 1.37M

Day Range

- - -

52 Wk Range

2.56 - 1.18K

Market Cap

$7.16M

P/E Ratio

-

Dividend Yield

-

Exchange

AMEX

RSI

50

Short Interest

2.9%

Days to Cover

1.66

About

Sector

Health Care

Industry

Biotechnology

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and rela...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Can Fite Biopharma (CANF) stock?

A

You can purchase shares of Can Fite Biopharma (AMEX:CANF) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Can Fite Biopharma (CANF) competitors?

A

Other companies in Can Fite Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Can Fite Biopharma (CANF) stock?

A

Can Fite Biopharma has a consensus price target of $10.75.

Q

What is the current price for Can Fite Biopharma (CANF)?

A

The stock price for Can Fite Biopharma (AMEX: CANF) is $3.34 last updated August 28, 2026 at 4:16 AM EDT.

Q

Does Can Fite Biopharma (CANF) pay a dividend?

A

There are no upcoming dividends for Can Fite Biopharma.

Q

When is Can Fite Biopharma (AMEX:CANF) reporting earnings?

A

Can Fite Biopharma does not have any upcoming earnings scheduled.

Q

Is Can Fite Biopharma (CANF) going to split?

A

There is no upcoming split for Can Fite Biopharma.

Q

What sector and industry does Can Fite Biopharma (CANF) operate in?

A

Can Fite Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.